(Total Views: 364)
Posted On: 09/26/2024 9:44:52 PM
Post# of 148870
What organ is IgG4-related to?
"IgG4-related disease (IgG4-RD) is a chronic, immune-mediated disorder that often manifests with multiorgan involvement and tumor-like masses most often affecting the pancreas, bile ducts, lacrimal glands, orbital tissues, salivary glands, lungs, kidneys, retroperitoneal tissues, aorta, meninges, and thyroid gland."
____
Cytodyn news:
" Leronlimab monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm (p<0.01)"
____
What is the treatment for IgG4?
Rituximab is nearly universally effective in treating active IgG4-RD.
Rituximab (Rituxan) can cause serious side effects, including:
Infection
Rituximab can increase the risk of infections, including bacterial, fungal, and viral infections. It can also lower the immune system's ability to fight infections.
Heart problems
Rituximab can cause heart and heart rhythm problems, including heart attack, arrhythmia, and cardiogenic shock.
Infusion-related reactions
Rituximab can cause life-threatening infusion-related reactions that require immediate medical attention. Symptoms include fever, chills, shaking, dizziness, trouble breathing, itching or rash, lightheadedness, or fainting.
GI obstruction or tear
Rituximab can cause bleeding or a tear in the intestinal wall. Signs include unexpected bleeding, blood in the stool or black stools, coughing up blood, vomiting blood, vomit that looks like coffee grounds, fever, severe pain in the abdomen, or new abdominal swelling.
Tumor lysis syndrome (TLS)
Rituximab can cause cancer cells to break down very quickly, releasing uric acid into the blood. The kidneys usually get rid of uric acid, but they may not be able to cope with large amounts. Too much uric acid can affect the kidneys and the heart.
Other serious side effects of Rituximab include unusual bruising or bleeding, earache, painful urination, chest tightness, and severe stomach pain or vomiting.
Ownership:
Genentech
Genentech co-markets rituximab in the United States with Biogen. Genentech financed the development of rituximab after partnering with IDEC in 1995. Roche acquired Genentech in 2009, completing the acquisition of the remaining 44% of shares.
Roche
Roche co-markets rituximab outside of the United States and Japan. Roche also uses the rituximab trademarked name MabThera.
Chugai Pharmaceuticals and Zenyaku Kogyo
Chugai Pharmaceuticals and Zenyaku Kogyo co-market rituximab in Japan.
_______
Looks like we can evolve into a partnership on Reversal, with a consortium, that is above Madrigal's pay grade. In turn, screwing them pretty good.
Or, or...all hell, who knows what mouse based agreement(s) were already hand shaked to.
Cytodyn has declared "significant fibrosis reversal".
Looks like the # of party attendees, is very likely more than 1. ( Madrigal )
Madrigal Vs Reversal Consortium?
LL's safety profile/industry $$ benefits alone, is an eventual threat to both groups.
"IgG4-related disease (IgG4-RD) is a chronic, immune-mediated disorder that often manifests with multiorgan involvement and tumor-like masses most often affecting the pancreas, bile ducts, lacrimal glands, orbital tissues, salivary glands, lungs, kidneys, retroperitoneal tissues, aorta, meninges, and thyroid gland."
____
Cytodyn news:
" Leronlimab monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm (p<0.01)"
____
What is the treatment for IgG4?
Rituximab is nearly universally effective in treating active IgG4-RD.
Rituximab (Rituxan) can cause serious side effects, including:
Infection
Rituximab can increase the risk of infections, including bacterial, fungal, and viral infections. It can also lower the immune system's ability to fight infections.
Heart problems
Rituximab can cause heart and heart rhythm problems, including heart attack, arrhythmia, and cardiogenic shock.
Infusion-related reactions
Rituximab can cause life-threatening infusion-related reactions that require immediate medical attention. Symptoms include fever, chills, shaking, dizziness, trouble breathing, itching or rash, lightheadedness, or fainting.
GI obstruction or tear
Rituximab can cause bleeding or a tear in the intestinal wall. Signs include unexpected bleeding, blood in the stool or black stools, coughing up blood, vomiting blood, vomit that looks like coffee grounds, fever, severe pain in the abdomen, or new abdominal swelling.
Tumor lysis syndrome (TLS)
Rituximab can cause cancer cells to break down very quickly, releasing uric acid into the blood. The kidneys usually get rid of uric acid, but they may not be able to cope with large amounts. Too much uric acid can affect the kidneys and the heart.
Other serious side effects of Rituximab include unusual bruising or bleeding, earache, painful urination, chest tightness, and severe stomach pain or vomiting.
Ownership:
Genentech
Genentech co-markets rituximab in the United States with Biogen. Genentech financed the development of rituximab after partnering with IDEC in 1995. Roche acquired Genentech in 2009, completing the acquisition of the remaining 44% of shares.
Roche
Roche co-markets rituximab outside of the United States and Japan. Roche also uses the rituximab trademarked name MabThera.
Chugai Pharmaceuticals and Zenyaku Kogyo
Chugai Pharmaceuticals and Zenyaku Kogyo co-market rituximab in Japan.
_______
Looks like we can evolve into a partnership on Reversal, with a consortium, that is above Madrigal's pay grade. In turn, screwing them pretty good.
Or, or...all hell, who knows what mouse based agreement(s) were already hand shaked to.
Cytodyn has declared "significant fibrosis reversal".
Looks like the # of party attendees, is very likely more than 1. ( Madrigal )
Madrigal Vs Reversal Consortium?
LL's safety profile/industry $$ benefits alone, is an eventual threat to both groups.
(3)
(0)Scroll down for more posts ▼
